The main cause of chronic bronchitis and emphysema is smoking; however, alpha1-antitrypsin also has been seen to cause emphysema in patients who are deficient. As symptoms and lung function decline, treatment modalities, such as lung volume reduction surgery, have been used in individuals with ...
Alpha1-Proteinase Inhibitor (Human), ZEMAIRA® is indicated to raise the plasma level of alpha1-proteinase inhibitor (A1-PI) in patients with A1-PI deficiency and related emphysema.
Alpha1-Proteinase Inhibitor (Human), ZEMAIRA® is indicated to raise the plasma level of alpha1-proteinase inhibitor (A1-PI) in patients with A1-PI deficiency and related emphysema.
Alpha1-Proteinase Inhibitor (Human), ZEMAIRA® is indicated to raise the plasma level of alpha1-proteinase inhibitor (A1-PI) in patients with A1-PI deficiency and related emphysema.
Alpha 1 antitrypsin (A1AT) is a serine protease inhibitor with anti-inflammatory and cytoprotective properties. We and others have shown benefits of A1AT in small and large animal lung transplant studies. Before performing clinical trials, evidence of therapeutic efficacy in human lungs would be ...
Correction: aralast: A new α1-protease inhibitor for treatment of α-antitrypsin deficiency To review the epidemiology, pathogenesis, and management of patients with alpha-antitrypsin (AAT) deficiency syndrome and compare Aralast with Prolastin, 2 of the 3 available human plasma-derived AAT agents...
Alpha1-antitrypsin deficiency (AATD) was first described by Laurell and Eriksson in 1963. Laurell noted the absence of the band of alpha1- protein in 5 of 1500 serum protein electrophoreses (SPEP) submitted to his laboratory in Sweden.
Alpha-1-antitrypsin (A1AT) deficiency is the commonest genetic cause of liver disease in children and chronic obstructive lung disease in young adult smokers.The pathogenetic mechanisms are completely different. While low serum levels of A1AT cause reduced alveolar elasticity and subsequent emphysema,...
Subjects with alpha-1 antitrypsin deficiency who develop pulmonary disease are managed following general treatment guidelines, including disease management interventions. In addition, administration of intravenous infusions of alpha-1 proteinase inhibito
Alpha! antitrypsin (AT) deficiency with both cirrhosis and chronic obstructive lung disease in two sibs. JOHN F. T. GLASGOW, AL- BERT HERCZ, HENRY LEVISON, MATTHEW J. LYNCH, and ANDREW SASS-KORTSAK. Univ. of Toronto, and Hosp. for Sick Children, Toronto, Ont., Canada. Three sibs (J...